Healthpeak (DOC) Reports Q3 Earnings: What Key Metrics Have to Say

Healthpeak (DOC) reported Q3 revenue of $705.87 million, a 0.8% year-over-year increase, surpassing consensus estimates by 1.42%, and an EPS of $0.46, beating estimates by 2.22%. However, the company posted a diluted net loss per share of $-0.17, significantly missing the analyst estimate of $0.05. Despite the operational beats, the stock has underperformed the S&P 500 over the past month and carries a Zacks Rank #4 (Sell), indicating a potential for near-term underperformance.

Analysis

Healthpeak (DOC) reported Q3 2025 revenue of $705.87 million, a 0.8% year-over-year increase, surpassing the Zacks Consensus Estimate of $696.02 million by 1.42%. The company also reported an EPS of $0.46, significantly higher than $0.12 a year ago and beating the consensus estimate of $0.45 by 2.22%. This indicates a strong top-line performance and growth in a key earnings metric.

However, a critical divergence emerged in profitability, with diluted Net Earnings per Share reported at $-0.17, a substantial miss against the average analyst estimate of $0.05. While rental and related revenues beat estimates at $539.89 million, representing a slight year-over-year decline of 0.6%, interest income and resident fees both missed their respective analyst estimates. This suggests underlying pressures despite the overall revenue beat.

The market has reacted cautiously, with DOC shares returning -0.2% over the past month, underperforming the S&P 500's +0.2% change. This underperformance, coupled with a Zacks Rank #4 (Sell), indicates a near-term expectation for the stock to underperform the broader market. The significant miss on diluted net EPS likely overshadows the positive top-line surprises.

Key Decisions for Investors

• Investors should scrutinize the discrepancy between the reported EPS of $0.46 and the diluted net EPS of $-0.17, understanding the underlying accounting definitions and their implications for true profitability.
• Given the significant miss on diluted net EPS, recent stock underperformance, and the Zacks Rank #4 (Sell), investors should exercise caution and consider the potential for continued near-term underperformance.
• Monitor future earnings reports for clarity on profitability trends and the performance of key revenue segments, particularly rental revenues which saw a year-over-year decline.